Day: November 13, 2025

GREENWICH, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) — Stardust Power Inc. (“Stardust Power” or the “Company”) (Nasdaq: SDST), an American developer of battery-grade lithium carbonate, today announced its results for the third quarter ended September 30, 2025.   Third Quarter 2025 Business Updates and Subsequent Events Operational highlights for the third quarter of 2025 include:The FEL-3 engineering report was completed for the Muskogee, Oklahoma lithium refinery, detailing Phase 1 capacity of 25,000 metric tons per annum (mtpa) (expandable to 50,000 mtpa), and estimated CapEx of approximately $500 million (including owner’s cost, contingency, and escalation), which is about $200 million below the prior estimate. The report outlined a 24-month construction timeline and a 90% probability of cost achievement. An independent third-party...

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now Being Treated at 160 mg Dose of TuspetinibSAN DIEGO and TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. “Tuspetinib in combination with VEN+AZA standard treatment (TUS+VEN+AZA) has been highly active and so well tolerated in newly diagnosed AML patients with 40 mg, 80 mg,...

HighlightsNet revenue of $1.7 billion, an increase of 11.8% compared to Q3 2024 Adjusted EBITDA1 increase of 17.8% to $323.4 million and adjusted EBITDA margin1 of 19.0%, a 100 basis point increase over Q3 2024 Diluted EPS of $1.32 and adjusted EPS1 of $1.53, up 46.7% and 17.7%, respectively, compared to Q3 2024 Contract backlog increased to $8.4 billion, up 14.9% year-over-year Increases full year adjusted EBITDA margin guidance, reflecting the strong performance year-to-date and expectations for Q4 2025.EDMONTON, Alberta and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Stantec (TSX, NYSE:STN), a global leader in sustainable engineering, architecture and environmental consulting, released its third quarter 2025 results today which were driven by the continued demand for Stantec’s services, its diversified business model,...

Adjusted EBITDA from continuing operations of $1.2 million for the nine months ended September 30, 2025, compared to a loss of $0.1 million in the year ago period Completed sale of Direct Sales Media Business and related creative assets in Q3, resulting in a gain on sale of subsidiaries and assets of $5.5 million Gross margin of 86.9% in Q3 2025, up 1,810 bps from Q3 2024 TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a digital publisher focused on building tools, platforms, and experiences for gamers, today announced financial results for the three months ended September 30, 2025 (“Q3 2025”). “In three short months we pushed squarely into profitability, increased our cash position significantly, and embraced our true identity as an R&D-driven,...

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or the “Company”) announced its operating and financial results for the third quarter and first nine months ended September 30, 2025. Highlights (Unless otherwise stated, all monetary figures in this news release are expressed in U.S. dollars, and all operational and financial information contained in this news release is related to continuing operations.)Record free cash flow generation: Generated $147.7 million of free cash flow1 and $184.5 million of cash provided from operating activities of continuing operations in the third quarter. Record adjusted net earnings per share: Reported third quarter adjusted net earnings1 of $129.2 million ($0.73 per share1) and net earnings from continuing operations of $96.0 million ($0.54...

Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites activated; on-track to dose first patient by year-endRecent data presented at EASD and IPSAD provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying, immunotherapeutic approach to redefine treatment of Stage 3 T1DStrong cash position with operational runway through 2028, enabling completion of registrational Phase 2b SAFEGUARD studyMIAMI, Nov. 13, 2025 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the third quarter ending September 30, 2025,...

CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (“Peyto” or the “Company”) is pleased to report operating and financial results for the third quarter of 2025 and a preliminary capital budget for 2026. Highlights:Peyto reported $198.9 million in funds from operations1,2 (“FFO”), or $0.98/diluted share, and generated $69.1 million of free funds flow3 in the quarter. Strong FFO was driven by the Company’s industry-leading low cash costs4 and realized natural gas price after hedging and diversification of $3.57/Mcf, or 3.3 times the AECO 7A monthly benchmark.        Earnings for the quarter totaled $90.7 million, or $0.45/diluted share, and Peyto returned $66.4 million as dividends to shareholders. Third quarter production volumes averaged 129,762 boe/d...

New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth HALIFAX, Nova Scotia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the second quarter of its fiscal year 2026, which ended on September 30, 2025. All figures are in Canadian dollars unless otherwise stated. “Strategic government partnerships are foundational to Appili’s impact in infectious disease and biodefense,” said Dr. Don Cilla, President and CEO...

VANCOUVER, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the “Company”) reports interim financial results for the quarter ended September 30, 2025. The interim financial statements and management’s discussion and analysis (“MD&A”) are available on Skeena’s website and have been posted under the Company’s profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Skeena would like to acknowledge the planned departure of Paul Geddes, Senior Vice President Exploration and Resource Development. The Company extends its gratitude to Mr. Geddes for his contributions throughout his eight year tenure. His technical expertise and leadership were instrumental in recognizing the exceptional potential of the Eskay Creek Project and advancing...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Nov. 13, 2025 (GLOBE NEWSWIRE) — Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company, today announced its unaudited financial results for the three and nine months ended September 30, 2025 (all amounts in U.S. dollars, unless otherwise indicated). The Company’s unaudited consolidated financial statements and management’s discussion and analysis (“MD&A”) for the three and nine-month period ended September 30, 2025, have been filed and made accessible under the Company’s continuous disclosure profile on SEDAR+ at www.sedarplus.ca and are also available on the...